August 23, 2024 at 8:52 am

Owlet Delivers Strong Q2 2024 Results and Sets New Sales Record on Amazon Prime Day

Owlet, Inc. (NYSE: OWLT), a leader in smart infant monitoring recently, announced financial results for Q2 2024, highlighted by significant revenue growth and improved profitability. The company also achieved record-breaking sales during Amazon Prime Day. Key Highlights: Revenue Growth: Q2 2024 revenue of $20.7 million, up 58% year-over-year. Improved Profitability: Net loss narrowed by 73%… [Read More]
August 22, 2024 at 12:36 pm

Lipella Pharmaceuticals (LIPO) Launches Patient Registry and Unveils Advanced Bladder Imaging Technique

The clinical stage biopharma company Lipella Pharmaceuticals (LIPO) has launched an Oral Lichen Planus (OLP) Patient Registry. This online platform is designed to enhance research and drive the development of new treatments for OLP, a chronic inflammatory disease affecting the mucous membranes of the mouth. OLP affects approximately 6M Americans and currently has no FDA-approved… [Read More]
August 22, 2024 at 11:09 am

BioPharma Emerger OS Therapies (OSTX) Appoints Significant ADC Board Member and is Accepted into Johnson & Johnson Innovation – JLABS

Today the ADC and Immunotherapy research and clinical-stage biopharmaceutical company, OS Therapies (OSTX) announced that it has appointed Borys Shor, PhD to its Antibody Drug Conjugate (ADC) Advisory Board. In his role, Dr. Shor will assist the Company in the selection of antibody and payloads to be developed using the Company’s tunable ADC platform leveraging… [Read More]
August 22, 2024 at 10:22 am

Clinical Validation and Commercial Launch Drive Oncocyte’s Progress

New Investor Deck Highlights Company Mission to Democratize Molecular Diagnostic Testing and Capture Market Share With significant momentum from its recent clinical publications and the successful beta launch of GraftAssureTM, which can detect early evidence of graft organ damage in a patient’s blood, Oncocyte Corporation (Nasdaq: OCX) recently shared its notable progress with investors in… [Read More]
August 22, 2024 at 10:13 am

Stocks Pare Gains Amid Weak Manufacturing Data and Fed Speculation: Markets Wrap Jobless Claims Show Gradual Cooling, Manufacturing Contracts at Fastest Pace This Year

Stocks pared gains as traders assessed mixed economic reports for hints on the Federal Reserve’s next moves. With Jerome Powell’s Jackson Hole speech on the horizon, data revealed that jobless claims indicate a slowly cooling labor market, while US manufacturing activity contracted at its fastest pace this year, driven by declines in production, orders, and… [Read More]
August 21, 2024 at 3:45 pm

Bright Green Corporation (BGXX) Announces Strategic Partnership with Benuvia Pharmaceuticals

Bright Green Corporation (Nasdaq: BGXX) ) a pioneer in growing and manufacturing Schedule I, the most stringent category of restricted drug substances and plant-based psychedelics, has teamed up with Benuvia Pharmaceuticals. The collaboration with Benuvia, a ground-breaking producer of pharmaceutical cannabinoids and psychedelic compounds in development for therapeutic purposes makes clear Bright Green’s commitment to… [Read More]
August 21, 2024 at 12:31 pm

Stronghold Digital Mining (SDIG) Gets Harvested by Bitfarms (BITF) for $175M in Stock and Assumed Debt, Shares Surge 70%

Stronghold Digital (SDIG) shares rose today ~70% on the announcement of its acquisition by Bitfarms (BITF). The transaction is valued at $125M equity value plus the assumption of ~$50M in debt. Stronghold is a vertically integrated crypto asset mining company focused on mining Bitcoin and environmental remediation and reclamation services. Stronghold owns over 750 acres… [Read More]
August 21, 2024 at 12:14 pm

BioStem Receives Institutional Review Board (IRB) Approval to Advance Clinical Study Evaluating the Value of Vendaje® Compared to the Standard of Care for Non-Healing Diabetic Foot Ulcers

The MedTech wound care leader BioStem Technologies (BSEM) announced that the Institutional Review Board (IRB) has approved a clinical study to evaluate Vendaje® for diabetic foot ulcers (DFU).  Study supports BioStem’s strategic growth initiatives and accelerates product adoption by providing data to healthcare professionals and payers on the benefits of Vendaje. Approximately 14 to 24… [Read More]
August 20, 2024 at 3:43 pm

Tonix Pharmaceuticals (TNXP) Doses First Patient in Phase 2 Study for Treating Cocaine Intoxication

Tonix Pharmaceuticals Holding Corp. (TNXP), an integrated biopharmaceutical and PRISM Pharma Index company with both marketed products and a pipeline of development candidates,  announced today that the first patient has been dosed in a Phase 2, single-blind, placebo-controlled proof-of-concept trial of TNX-1300. This trial is investigating TNX-1300, a double-mutant cocaine esterase (200 mg, i.v. solution),… [Read More]
August 20, 2024 at 9:53 am

PRISM Cannabis News Roundup: Fentanyl Fears, Legal Loopholes, and the Battle Over Buffer Zones

JD Vance’s Controversial Claims on Fentanyl-Laced Marijuana Senator JD Vance, Donald Trump’s running mate, recently sparked controversy by claiming that fentanyl-laced marijuana is becoming widespread. Speaking at the Milwaukee Police Association’s headquarters, Vance laid blame on Vice President Kamala Harris, citing the opioid crisis and Mexican cartels. However, the Drug Enforcement Administration (DEA) has confirmed… [Read More]